Macrophages play a key role in the pathogenesis of various autoimmune and rheumatic diseases. An important mechanism by which activated macrophages contribute to disease pathogenesis is production of inflammatory cytokines such as TNF, IL-1 and IL-6. These cytokines are canonical NF-?B target genes and validated therapeutic targets. The long term goals of this project are to understand how inflammatory macrophage activation is regulated, with the associated goal of developing new therapies that selectively suppress pathogenic macrophage functions, while preserving homeostatic functions and host defense. Type I IFNs and IFN-? are important regulators of immunity and inflammation. IFNs activate the JAK- STAT signaling pathway to induce canonical interferon-stimulated genes (ISGs). Expression of IFN target genes (termed an ?IFN signature?) is one of the most prominent molecular pathways activated in several autoimmune diseases including RA, lupus nephritis, and macrophage activation syndrome (MAS) (and related familial hemophagocytic lymphohistiocytosis (fHLH)). IFNs are clearly pathogenic in monogenic ?interferonopathies? and fHLH, where patients are responsive to JAK inhibitors and IFN-? blockade. JAK inhibitors, which target IFNs amongst other cytokines, are effective in RA and are being tested in SLE. Although IFNs do not directly activate pathogenic non-ISG inflammatory NF-?B target genes such as TNF, IL1B and IL6, they potentiate induction of these genes by TNF and TLRs. This supports the possibility that the therapeutic efficacy of IFN blockade or Jak inhibitors may be mediated at least in part by direct suppression of inflammatory cytokine production in macrophages. In accord with this notion, JAK inhibitors decrease inflammatory responses and cytokines in RA patients, primed human macrophages, RA synovial macrophages and tissue explants, and in preclinical models of arthritis and MAS/fHLH. In the previous project period we found that IFN-JAK-STAT signaling induces chromatin remodeling at inflammatory NF-?B target genes to make these genes hyper-responsive to inflammatory signals and resistant to suppression. IFNs also selectively suppressed components of the macrophage response to the suppressive cytokine IL-10 by deactivating enhancers. These data provide insights into pathways that connect IFN-JAK-STAT signaling to inflammatory NF-?B target genes and support our overarching hypothesis that IFNs help drive inflammatory non-ISG gene expression via chromatin-based mechanisms. In this project we will investigate epigenetic mechanisms by which IFNs drive macrophage activation and expression of pathogenic NF-?B target genes such as TNF, IL1B and IL6, and mechanisms by which JAK inhibitors suppress these genes. We anticipate that our studies will yield insights that can be used to develop novel therapeutic strategies to suppress inflammatory responses, and help understand how epigenetic mechanisms can contribute to poor efficacy of therapies that target upstream signaling pathways.

Public Health Relevance

Macrophages have been implicated in several autoimmune diseases, including rheumatoid arthritis (RA), lupus kidney disease, and macrophage activation syndrome. The long term goals of this project are to understand how inflammatory macrophage activation (and de-activation) are regulated, and to use this knowledge to develop new therapies. This project will focus on understanding regulation of macrophage genes and pathways that play a key role in increasing inflammatory responses to gain knowledge that can be used to turn off macrophages to effectively and safely treat autoimmune and inflammatory diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI046712-21
Application #
9969673
Study Section
Hypersensitivity, Autoimmune, and Immune-mediated Diseases Study Section (HAI)
Program Officer
Peyman, John A
Project Start
2000-03-01
Project End
2025-02-28
Budget Start
2020-03-01
Budget End
2021-02-28
Support Year
21
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Hospital for Special Surgery
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10021
Sokhi, Upneet K; Liber, Mark P; Frye, Laura et al. (2018) Dissection and function of autoimmunity-associated TNFAIP3 (A20) gene enhancers in humanized mouse models. Nat Commun 9:658
Binder, Nikolaus; Miller, Christine; Yoshida, Masaki et al. (2017) Def6 Restrains Osteoclastogenesis and Inflammatory Bone Resorption. J Immunol 198:3436-3447
Park, Sung Ho; Kang, Kyuho; Giannopoulou, Eugenia et al. (2017) Type I interferons and the cytokine TNF cooperatively reprogram the macrophage epigenome to promote inflammatory activation. Nat Immunol 18:1104-1116
Kang, Kyuho; Park, Sung Ho; Chen, Janice et al. (2017) Interferon-? Represses M2 Gene Expression in Human Macrophages by Disassembling Enhancers Bound by the Transcription Factor MAF. Immunity 47:235-250.e4
Ivashkiv, Lionel B; Park, Sung Ho (2016) Epigenetic Regulation of Myeloid Cells. Microbiol Spectr 4:
Qiao, Yu; Kang, Kyuho; Giannopoulou, Eugenia et al. (2016) IFN-? Induces Histone 3 Lysine 27 Trimethylation in a Small Subset of Promoters to Stably Silence Gene Expression in Human Macrophages. Cell Rep 16:3121-3129
Lee, Min Joon; Lim, Elisha; Mun, Sehwan et al. (2016) Intravenous Immunoglobulin (IVIG) Attenuates TNF-Induced Pathologic Bone Resorption and Suppresses Osteoclastogenesis by Inducing A20 Expression. J Cell Physiol 231:449-458
Miller, Christine H; Smith, Sinead M; Elguindy, Mahmoud et al. (2016) RBP-J-Regulated miR-182 Promotes TNF-?-Induced Osteoclastogenesis. J Immunol 196:4977-86
Huynh, Linda; Kusnadi, Anthony; Park, Sung Ho et al. (2016) Opposing regulation of the late phase TNF response by mTORC1-IL-10 signaling and hypoxia in human macrophages. Sci Rep 6:31959
Kalliolias, George D; Ivashkiv, Lionel B (2016) TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol 12:49-62

Showing the most recent 10 out of 53 publications